VJHemOnc is committed to improving our service to you

COSTEM 2019 | Can third party CMV-specific T-cells replace drug therapy?

VJHemOnc is committed to improving our service to you

Per Ljungman

Per Ljungman, MD, PhD, Karolinska University Hospital, Solna, Sweden, evaluates third-party CMV-specific T-cells replacing drug therapy. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter